Weight Loss
Orforglipron Side Effects: What to Expect and How to Manage Them
Orforglipron, sold under the brand name Foundayo, has a side effect profile that looks a lot like other GLP-1 medications. The most common reactions…
Foundayo (Orforglipron): The FDA-Approved Weight Loss Pill
Orforglipron is now approved and on the market under the brand name Foundayo. The FDA approved it on April 1, 2026, for adults with…
Survodutide vs CagriSema: Two Investigational Obesity Drugs Compared
Survodutide and CagriSema are both investigational obesity drugs, but they come from different companies and use different hormone combinations. Survodutide (Boehringer Ingelheim and Zealand…
Amycretin vs CagriSema: How Novo Nordisk’s Two Next-Gen Obesity Drugs Compare
Amycretin and CagriSema are both Novo Nordisk obesity programs that pair GLP-1 with amylin, two appetite hormones, but they go about it differently. CagriSema…
Amycretin vs Retatrutide: How Two Next-Generation Weight Loss Drugs Compare
Amycretin and retatrutide are two of the most closely watched experimental obesity drugs in development, and they come from the two companies that already…
Survodutide vs Retatrutide: Dual vs Triple Agonist
Survodutide and retatrutide are both investigational obesity drugs that add glucagon to GLP-1, but retatrutide goes a step further by also targeting GIP. Neither…
Retatrutide vs CagriSema: How the Two Next-Gen Drugs Compare
Retatrutide and CagriSema are both investigational obesity drugs that outperform current medications in trials, and neither is FDA approved or available by prescription, from…
Retatrutide Half-Life: How Long It Stays in Your System
Retatrutide has a half-life of about six days. That single number explains a lot: it is why the drug is injected once a week,…
Retatrutide Benefits Beyond Weight Loss: What the Trials Show
Weight loss gets the headlines, but in clinical trials retatrutide has shown effects that reach well past the scale: better blood sugar, less liver…
